vs
Celularity Inc（CELU）与Rithm Property Trust Inc.（RPT）财务数据对比。点击上方公司名可切换其他公司
Celularity Inc的季度营收约是Rithm Property Trust Inc.的1.6倍（$5.3M vs $3.4M），Rithm Property Trust Inc.净利率更高（95.4% vs -436.7%，领先532.1%），Rithm Property Trust Inc.同比增速更快（-39.7% vs -43.2%），过去两年Celularity Inc的营收复合增速更高（-33.9% vs -43.2%）
Celularity Inc是一家临床阶段生物技术企业，专注于开发胎盘来源的即用型细胞疗法与免疫疗法，用于治疗癌症、自身免疫性疾病及退行性疾病，主要面向美国市场，产品管线覆盖肿瘤学、再生医学、传染病等领域。
Rithm Property Trust Inc.旗下的里思资本是一家总部位于纽约的美国投资管理公司，核心业务聚焦于房地产投资及另类投资领域，是该赛道颇具影响力的专业投资机构。
CELU vs RPT — 直观对比
营收规模更大
CELU
是对方的1.6倍
$3.4M
营收增速更快
RPT
高出3.5%
-43.2%
净利率更高
RPT
高出532.1%
-436.7%
两年增速更快
CELU
近两年复合增速
-43.2%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $5.3M | $3.4M |
| 净利润 | $-23.1M | $3.2M |
| 毛利率 | 26.1% | — |
| 营业利润率 | -244.1% | 99.6% |
| 净利率 | -436.7% | 95.4% |
| 营收同比 | -43.2% | -39.7% |
| 净利润同比 | -43.3% | 11.2% |
| 每股收益（稀释后） | $-0.88 | $-0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CELURPT
| Q4 25 | — | $3.4M | ||
| Q3 25 | $5.3M | $4.0M | ||
| Q2 25 | $5.7M | $4.2M | ||
| Q1 25 | $11.4M | $249.0K | ||
| Q4 24 | $18.1M | — | ||
| Q3 24 | $9.3M | — | ||
| Q2 24 | $12.1M | — | ||
| Q1 24 | $14.7M | — |
净利润CELURPT
| Q4 25 | — | $3.2M | ||
| Q3 25 | $-23.1M | $-273.0K | ||
| Q2 25 | $-24.5M | $1.9M | ||
| Q1 25 | $-19.8M | $-3.4M | ||
| Q4 24 | $-13.3M | — | ||
| Q3 24 | $-16.1M | — | ||
| Q2 24 | $-6.5M | — | ||
| Q1 24 | $-22.0M | — |
毛利率CELURPT
| Q4 25 | — | — | ||
| Q3 25 | 26.1% | — | ||
| Q2 25 | 8.6% | — | ||
| Q1 25 | 68.9% | — | ||
| Q4 24 | 59.5% | — | ||
| Q3 24 | 58.2% | — | ||
| Q2 24 | 82.5% | — | ||
| Q1 24 | 88.8% | — |
营业利润率CELURPT
| Q4 25 | — | 99.6% | ||
| Q3 25 | -244.1% | -6.2% | ||
| Q2 25 | -276.6% | 45.7% | ||
| Q1 25 | -91.8% | -1416.5% | ||
| Q4 24 | -51.2% | — | ||
| Q3 24 | -124.0% | — | ||
| Q2 24 | -84.0% | — | ||
| Q1 24 | -50.2% | — |
净利率CELURPT
| Q4 25 | — | 95.4% | ||
| Q3 25 | -436.7% | -6.8% | ||
| Q2 25 | -427.5% | 45.1% | ||
| Q1 25 | -172.9% | -1363.1% | ||
| Q4 24 | -73.3% | — | ||
| Q3 24 | -173.2% | — | ||
| Q2 24 | -53.6% | — | ||
| Q1 24 | -149.9% | — |
每股收益（稀释后）CELURPT
| Q4 25 | — | $-0.26 | ||
| Q3 25 | $-0.88 | $-0.03 | ||
| Q2 25 | $-1.02 | $0.01 | ||
| Q1 25 | $-0.84 | $-0.08 | ||
| Q4 24 | $-0.58 | — | ||
| Q3 24 | $-0.73 | — | ||
| Q2 24 | $-0.30 | — | ||
| Q1 24 | $-1.03 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $120.0K | $79.3M |
| 总债务越低越好 | $35.7M | — |
| 股东权益账面价值 | $-20.1M | $291.6M |
| 总资产 | $114.2M | $1.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CELURPT
| Q4 25 | — | $79.3M | ||
| Q3 25 | $120.0K | $81.4M | ||
| Q2 25 | $863.0K | $98.6M | ||
| Q1 25 | $293.0K | $97.4M | ||
| Q4 24 | $738.0K | — | ||
| Q3 24 | $133.0K | — | ||
| Q2 24 | $467.0K | — | ||
| Q1 24 | $1.9M | — |
总债务CELURPT
| Q4 25 | — | — | ||
| Q3 25 | $35.7M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益CELURPT
| Q4 25 | — | $291.6M | ||
| Q3 25 | $-20.1M | $291.7M | ||
| Q2 25 | $-25.5M | $294.7M | ||
| Q1 25 | $-5.5M | $296.1M | ||
| Q4 24 | $8.8M | — | ||
| Q3 24 | $17.3M | — | ||
| Q2 24 | $27.8M | — | ||
| Q1 24 | $31.2M | — |
总资产CELURPT
| Q4 25 | — | $1.0B | ||
| Q3 25 | $114.2M | $1.0B | ||
| Q2 25 | $120.3M | $1.0B | ||
| Q1 25 | $128.9M | $1.0B | ||
| Q4 24 | $132.7M | — | ||
| Q3 24 | $128.8M | — | ||
| Q2 24 | $135.5M | — | ||
| Q1 24 | $143.8M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-4.2M | $-8.3M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | -2.56× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CELURPT
| Q4 25 | — | $-8.3M | ||
| Q3 25 | $-4.2M | $-5.8M | ||
| Q2 25 | $-999.0K | $-25.0K | ||
| Q1 25 | $-3.0M | $-1.6M | ||
| Q4 24 | $1.6M | — | ||
| Q3 24 | $-144.0K | — | ||
| Q2 24 | $-3.4M | — | ||
| Q1 24 | $-4.4M | — |
自由现金流CELURPT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $1.5M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-3.5M | — | ||
| Q1 24 | $-4.4M | — |
自由现金流率CELURPT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 8.3% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -28.7% | — | ||
| Q1 24 | -30.3% | — |
资本支出强度CELURPT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.5% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.3% | — | ||
| Q1 24 | 0.3% | — |
现金转化率CELURPT
| Q4 25 | — | -2.56× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.01× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CELU
| License Royalty And Other | $2.9M | 56% |
| Degenerative Disease | $2.2M | 42% |
RPT
暂无分部数据
